Haematological effects of COVID-19 infection [COVID-19]
Research type
Research Study
Full title
An observational study to evaluate the haematological changes caused by COVID-19 infection and their association with thrombotic clinical outcomes.
IRAS ID
282457
Contact name
Nicola Curry
Contact email
Sponsor organisation
Oxford University Hospitals NHS Foundation Trust
ISRCTN Number
ISRCTN64783542
Duration of Study in the UK
0 years, 6 months, 1 days
Research summary
Infection rates with COVID-19 are rising rapidly across the UK. Doctors are noticing in the first groups of patients admitted to hospital that there are unusual abnormalities in the blood test results, most evident in the blood clotting tests. This is particularly marked in patients who end up with the most severe type of COVID-19 lung infection. Early studies from China also highlighted these clotting abnormalities. It seems that small clots develop in the lungs and sometimes in the kidneys and this causes these organs to fail. There can also be the development of larger clots, such as those found in the large blood vessels of the lung (pulmonary emboli) and legs (deep vein thrombosis). This pattern of clots is highly unusual and needs further investigation. We would like to document the changes to clotting tests in all patients admitted to hospital with COVID-19, and compare the tests from those patients who require intensive care treatment with those whose illness does not develop so aggressively. We are particularly interested in whether there is a higher than normal risk for COVID-19 patients to develop blood clots (both large and small types of clot). We hope to be able to use these data to look at: 1) if we can use the basic blood test results to predict if a patient is likely to require more intensive therapy; 2) if the blood results can be used to predict if a patient will develop small clots and/or large clots; 3) the likelihood that a patient with COVID-19 will develop a blood clot while in hospital or after being sent home and 4) whether any treatments given as routine care reduce those risks. We aim to use these results also to understand whether we need to develop new clot prevention strategies.\n
REC name
London - London Bridge Research Ethics Committee
REC reference
20/HRA/2304
Date of REC Opinion
6 May 2020
REC opinion
Favourable Opinion